Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jul 28, 2016; 22(28): 6484-6500
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6484
Table 2 Prospective studies on HBV reactivation in haematology patients with resolved hepatitis B virus infection (HBsAg negative anti-HBc positive patients)
Author/yearDiseaseStudy designSample sizeDefinition of HBV reactivationRate of HBV reactivationRisk factor(s) identified for HBV reactivationDeath from HBV reactivation
Yeo et al[99] 2009Diffuse large B-cell lymphomaAll patients were observed every 2-3 wk during anticancer therapy and every 6-8 wk for 9 mo after anticancer therapy46HBsAg seroconversion (the reappearance of HBsAg) with an increase in HBV DNA levels when compared with baseline HBV DNA levels, in the absence of acute infection with HAV, HCV, or other systemic infections25% in patients receiving R-CHOPAbsence of anti-HBs, use of rituximab and male sex20% died of HBV reactivation
Start lamivudine upon HBV reactivation
Huang et al[107] 2013B-cell lymphomaEntecavir prophylaxis (continued until 3 mo after completing chemotherapy) vs preemptive treatment80Elevation of HBV viral load to 2000 IU/mL with two consecutive determinations (2 wk apart)Incidence was 4.3% in entecavir group and 25.9% in the control group at 1.5 yrLack of entecavir prophylaxisNil
Seto et al[45] 2014CD20 positive B-cell lymphomaHBV DNA monitoring every 4 wk63HBV DNA ≥ 10 IU/mL2-yr cumulative rate 41.5%Anti-HBs < 10 mIU/mLNil
Start entecavir upon detection of HBV reactivation
Hsu et al[16] 2014CD20 positive B-cell lymphomaHBV DNA monitoring every 4 wk150> 10-fold increase in HBV DNA, compared with previous nadir levelsIncidence was 10.4%Absence of anti-HBsNil
Start entecavir upon detection of HBV reactivation
Kusumoto et al[46] 2015CD20 positive B-cell lymphomaHBV DNA monitoring every 4 wk269HBV DNA ≥ 11 IU/mLIncidence was 8.3% at 1.5 yrAnti-HBs < 10 mIU/mL and baseline HBV DNA below level of quantificationNil
Start entecavir upon detection of HBV reactivation